For patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiators of rivaroxaban or warfarin versus apixaban have significantly higher rates of major hemorrhage, according to a study ...

Please provide your email address to receive an email when new articles are posted on . Among patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to ...

Rivaroxaban, a direct oral anticoagulant (DOAC), demonstrated greater efficacy and similar safety compared with warfarin in patients with chronic kidney disease and atrial fibrillation. Rivaroxaban, a ...

NEW ORLEANS, March 18, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new real-world study, which found newly diagnosed patients with ...

Please provide your email address to receive an email when new articles are posted on . Acute left ventricular thrombus occurs in about 3% of all patients with STEMI. Rivaroxaban demonstrated similar ...

ATLANTA, Georgia — Patients with atrial fibrillation receiving anticoagulant therapy are more likely to experience gastrointestinal (GI) bleeding when treated with rivaroxaban than when treated with ...

The direct oral anticoagulants (DOACs) took cardiology by storm a decade ago when trials showed they were at least as safe and effective as warfarin for several indications, especially reducing stroke ...

NATIONAL HARBOR, MD—In patients with A-fib who require TAVR, rivaroxaban (Xarelto; Bayer/Janssen) and warfarin appear equally effective at preventing stroke out to 3 years, according to the results of ...

At three months of follow-up, patients hospitalized for a serious heart attack who were treated with the oral blood thinner rivaroxaban for a blood clot in the left ventricle did as well as similar ...

Initiators of rivaroxaban or warfarin vs apixaban have significantly higher rates of major hemorrhage. HealthDay News — For patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiators ...